Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.38 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11953213 | 1.00 | ATM (0.44) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL14610923 | 1.00 | ATM (0.44) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL16852134 | 1.00 | ATM (0.44) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL26724067 | 1.00 | ATM (0.44) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL9108324 | 0.84 | ATM (0.53) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL22853605 | 0.84 | ATM (0.53) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL10021563 | 0.84 | ATM (0.53) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL9107535 | 0.84 | ATM (0.53) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL10105388 | 0.84 | ATM (0.53) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL19090801 | 0.84 | ATM (0.53) | ATMPIK3CDDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20120165315-A1 | MEPTAZINOL CARBAMATE PRODRUG SALTS | JOSTENS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165315-A1 | MEPTAZINOL CARBAMATE PRODRUG SALTS | MEP1A, MEP1B, CTSZ | ATM 4278/4885PIK3CD 2907/4885DPP4 48/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | ATM 540/4885PIK3CD 133/4885DPP4 1948/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | ATM 3657/4885PIK3CD 3966/4885DPP4 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.